文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛消化、代谢与肾脏急症

二甲双胍通过促进AMPK激活并抑制HIF-1α诱导的有氧糖酵解减轻脓毒症相关肺纤维化

METFORMIN MITIGATES SEPSIS-ASSOCIATED PULMONARY FIBROSIS BY PROMOTING AMPK ACTIVATION AND INHIBITING HIF-1α-INDUCED AEROBIC GLYCOLYSIS.
PubMed 文献 · Shock · 2023-11-15
一句话结论细胞与小鼠实验提示,二甲双胍经AMPK激活、抑制HIF-1α诱导的有氧糖酵解,可能减轻脓毒症相关肺纤维化(作者认为可能是有用的治疗选择)。

研究旨在验证AMPK激活与抑制HIF-1α诱导的有氧糖酵解在脓毒症肺纤维化形成中的核心作用。细胞实验显示脂多糖通过AMPK失活、HIF-1α诱导及有氧糖酵解增强促进成纤维细胞活化,而AMPK激活或HIF-1α抑制可逆转上述效应。小鼠实验中,AMPK激活剂二甲双胍预处理可抑制HIF-1α表达并减轻脓毒症相关肺纤维化;HIF-1α敲低在体内显示相似保护作用。作者据此认为,以二甲双胍靶向AMPK激活与HIF-1α诱导的有氧糖酵解,可能成为脓毒症相关肺纤维化实用且有用的治疗替代方案。

要点

  • 细胞实验:脂多糖经AMPK失活、HIF-1α诱导及有氧糖酵解增强促进成纤维细胞活化,AMPK激活或HIF-1α抑制可逆转该效应。
  • 小鼠实验:AMPK激活剂二甲双胍预处理抑制HIF-1α表达,减轻脓毒症相关肺纤维化。
  • 小鼠实验:HIF-1α敲低在体内显示与二甲双胍相似的肺纤维化保护作用。
  • 作者认为靶向AMPK激活与HIF-1α诱导的有氧糖酵解(二甲双胍)可能是脓毒症相关肺纤维化实用且有用的治疗替代方案。

适用人群与场景

  • 脓毒症相关肺纤维化的细胞实验与小鼠模型;原文未给出临床患者纳入或排除人群

处置流程与药物剂量

  • 小鼠实验中采用二甲双胍预处理(AMPK激活剂),可抑制HIF-1α表达并减轻脓毒症相关肺纤维化;原文未给出剂量、给药途径、频次或疗程。

研究设计与关键结果

  • 细胞实验显示脂多糖通过AMPK失活、HIF-1α诱导及有氧糖酵解增强促进成纤维细胞活化;AMPK激活或HIF-1α抑制可逆转上述效应。
  • 小鼠实验中,AMPK激活剂二甲双胍预处理抑制HIF-1α表达并减轻脓毒症相关肺纤维化;HIF-1α敲低在体内显示相似保护作用。

证据类型、等级与局限

  • 证据类型:细胞实验与小鼠在体实验(基础研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,以二甲双胍靶向AMPK激活与HIF-1α诱导的有氧糖酵解,可能是脓毒症相关肺纤维化实用且有用的治疗替代方案;该结论来自细胞与小鼠实验,原文未给出临床用药方案。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Recent research has revealed that aerobic glycolysis has a strong correlation with sepsis-associated pulmonary fibrosis (PF). However, at present, the mechanism and pathogenesis remain unclear. We aimed to test the hypothesis that the adenosine monophosphate-activated protein kinase (AMPK) activation and suppression of hypoxia-inducible factor 1α (HIF-1α)-induced aerobic glycolysis play a central role in septic pulmonary fibrogenesis. Cellular experiments demonstrated that lipopolysaccharide increased fibroblast activation through AMPK inactivation, HIF-1α induction, alongside an augmentation of aerobic glycolysis. By contrast, the effects were reversed by AMPK activation or HIF-1α inhibition. In addition, pretreatment with metformin, which is an AMPK activator, suppresses HIF-1α expression and alleviates PF associated with sepsis, which is caused by aerobic glycolysis, in mice. Hypoxia-inducible factor 1α knockdown demonstrated similar protective effects in vivo . Our research implies that targeting AMPK activation and HIF-1α-induced aerobic glycolysis with metformin might be a practical and useful therapeutic alternative for sepsis-associated PF.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Zhong H, Tang R, Feng JH, et al. METFORMIN MITIGATES SEPSIS-ASSOCIATED PULMONARY FIBROSIS BY PROMOTING AMPK ACTIVATION AND INHIBITING HIF-1α-INDUCED AEROBIC GLYCOLYSIS. Shock. 2023. PMID: 38010091. doi:10.1097/SHK.0000000000002275

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。